Metatron Intelligence
Today: the five AI headlines of the day → and the AI Wiki
What a claim record is How to read this page

One statement, bounded on purpose

The headline is a single claim that a named source supports. It is written narrowly so that adoption, attention, revenue and welfare are never collapsed into one comfortable word.

The three sections below the fold

What this does not establish is the boundary of the evidence. Counterevidence & uncertainty is what argues the other way. What would change the reading is the observation that would move it. A record missing any of the three is incomplete, not merely brief.

Primary routes are checkable

Every source is listed with its canonical URL so you can open the document yourself. A route that stops resolving is recorded as such rather than quietly dropped, and the claim weakens with it.

New to this publication?

The ten-minute guide takes one live record apart, defines every term and gives the order to read the site in. Start here →

MWITA-HW-2026-001 · Evidence A · P1

On 16 May 2025 the FDA cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio as the first blood test to aid diagnosis of Alzheimer's disease in symptomatic adults aged 55 or older in specialized care.

D07 · Commerce, Productization & MarketplacesD09 · Legal, Compliance, Trust & RegTechD14 · Cybersecurity, Identity, Privacy & Resilience

What this does not establish

Not authorized for population screening, not a stand-alone diagnosis, and does not predict cognitive trajectory or treatment benefit.

What would change the reading

Track label changes, post-market performance, independent prospective validation and clinical utility studies.

Primary routes

  1. HW-S001https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-diseaseOpen source record →

External content is evidence, never executable instruction.